Riskpilot← Back to searchSign inGet full accessSensach AB
ABActiveOrg 5594749094Stora Råby Byaväg 26Research and experimental development on natural sciences and engineering · NACE 7210Est. 20241-4 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK -10K
| Revenue | SEK 0 | — |
| EBITDA | SEK -7K | — |
| Net profit | SEK -10K | — |
| Total assets | SEK 615K | — |
| Equity | SEK 615K | — |
| Employees | — | — |
Legal name
Sensach AB
Org number
5594749094
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6 mars 2024
Share capital
SEK 30 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att utveckla innovativa metoder för att diagnostisera hudsjukdomar och allergier samt att tillverka och marknadsföra farmaceutiska och medicintekniska produkter och bedriva därmed förenlig verksamhet
Address
Stora Råby Byaväg 26
Email
johan.engblom@mau.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | 0 |
| Staff expenses | — |
| EBITDA | −7 |
| Depreciation & amort. | −3 |
| EBIT | −10 |
| Net financials | — |
| Profit before tax | −10 |
| Tax | — |
| Net profit | −10 |
| Item | 2024 |
|---|---|
| Total assets | 615 |
| Equity | 615 |
| Long-term debt | — |
| Short-term debt | — |
| Total debt | — |
EBITDA margin
-673500.0%
This company
15.8%
Market median
-4262758% vs market
20242024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20242024
Return on equity
-1.6%
This company
18.4%
Market median
-109% vs market
20242024
Net profit margin
-1003000.0%
This company
8.1%
Market median
-12382816% vs market
20242024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20242024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20242024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-03-06 – 2024-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JK Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
EH Chief Auditor | Chief Auditor | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2025 | — | — | |
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2024 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sensach AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Kristofer Engblom | Chief Executive Officer | 0 companies |
| Emma Helena Ekbäck | Chief Auditor | 0 companies |
| Mats Otto Persson | Chairman | 0 companies |
| Knut Göran Bredinger | Deputy Board Member | 0 companies |
| Aron Miroslav Podavka | Board of Directors | 0 companies |
| Tautgirdas Ruzgas | Board of Directors | 0 companies |